Striatal adenosine A 2A receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [ 18F]-MRS5425

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 897-906

  Bhattacharjee, Abesh Kumar ^a   Lang, Lixin ^a   Jacobson, Orit ^a   Shinkre, Bidhan ^b   Ma, Ying ^a   Niu, Gang ^a,c   Trenkle, William C ^b   Jacobson, Kenneth A ^b   Chen, Xiaoyuan ^a   Kiesewetter, Dale O ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

6 OHDA; Adenosine A 2A; MRS5425; Parkinson's disease; Rat; SCH442416

Indexed keywords

2 (FURAN 2 YL) 7 (3 (4 METHOXYPHENYL)PROPYL) 7H PYRAZOLO [4,3 E] [1,2,4]TRIAZOLO [1,5 C]PYRIMIDINE 5 AMINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 7 (3 (4 (2 FLUOROETHOXY)PHENYL)PROPYL) 2 (FURAN 2 YL) 7H PYRAZOLO [4,3 E] [1,2,4] TRIAZOLO [1,5 C]PYRIMIDIN 5 AMINE F 18; ADENOSINE A2 RECEPTOR; MRS 5425; OXIDOPAMINE; QUINPIROLE; RACLOPRIDE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; DRUG SYNTHESIS; HEMISPHERE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; ISOTOPE LABELING; LIPOPHILICITY; MALE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; SUBSTANTIA NIGRA;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT; INJECTIONS; MALE; NEOSTRIATUM; OXIDOPAMINE; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIMIDINES; QUINPIROLE; RACLOPRIDE; RADIOCHEMISTRY; RATS; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 80051691328     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.01.009     Document Type: Article

References (47)

1. Ferre S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997, 20:482-487.
2. 2A receptors. Trends Pharmacol Sci 1996, 17:364-372.
3. Cunha R.A., Johansson B., van der Ploeg I., Sebastiao A.M., Ribeiro J.A., Fredholm B.B. Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res 1994, 649:208-216.
4. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992, 14:186-195.
5. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991, 57:1062-1067.
6. 2A receptors. Prog Neurobiol 1999, 59:355-396.
7. 2A adenosine receptors after persistent D2 dopamine receptor activation. J Pharmacol Exp Ther 2004, 308:221-227.
8. 2A receptor antagonist. J Neurosci 2000, 20:5848-5852.
9. 2A adenosine receptors. J Neurosci 2002, 22:1054-1062.
10. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006, 29:647-654.
11. Hornykiewicz O. Imbalance of brain monoamines and clinical disorders. Prog Brain Res 1982, 55:419-429.
12. Heiss W.D., Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004, 11:5-12.
13. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996, 103:987-1041.
14. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971, 367:69-93.
15. Jeon B.S., Jackson-Lewis V., Burke R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995, 4:131-137.
16. Arnt J., Hyttel J. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology 1985, 85:346-352.
17. Yuan H., Sarre S., Ebinger G., Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 2005, 144:35-45.
18. Cadet J.L., Zhu S.M. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res 1992, 595:316-326.
19. Chalon S., Emond P., Bodard S., Vilar M.P., Thiercelin C., Besnard J.C., et al. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse (New York, N.Y 1999, 31:134-139.
20. Ichise M., Kim Y.J., Ballinger J.R., Vines D., Erami S.S., Tanaka F., et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in l-DOPA-untreated PD. Neurology 1999, 52:1206-1214.
21. 2A receptor mRNA by dopamine denervation. Eur J Pharmacol 2002, 446:75-82.
22. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995, 52:1183-1190.
23. 2A receptor mRNA expression in Parkinson's disease. Neuroscience letters 2000, 291:54-58.
24. 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. Faseb J 2010, 24:587-598.
25. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 1998, 339:1130-1143.
26. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
27. Bhattacharjee A.K., Meister L.M., Chang L., Bazinet R.P., White L., Rapoport S.I. In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease. Neuroimage 2007, 37:1112-1121.
28. 3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp Ther 2001, 296:1074-1084.
29. 2A receptors in normal human brain measured with [C-11]TMSX PET. Synapse (New York, N.Y 2007, 61:778-784.
30. 2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 2010, 33:55-60.
31. Musachio J.L., Shah J., Pike V.W. Radiosyntheses and reactivities of novel [F-18]2-fluoroethyl arylsulfonates. J. Label. Compd. Radiopharm 2005, 48:735-747.
32. Ma Y., Kiesewetter D., Lang L., Eckelman W.C. Application of LC-MS to the analysis of new radiopharmaceuticals. Mol Imaging Biol 2003, 5:397-403.
33. 2A receptor-selective antagonists. Bioorg Med Chem Lett 2010, 20:5690-5694.
34. 2A adenosine receptor antagonists. J Med Chem 1998, 41:2126-2133.
35. Inaji M., Okauchi T., Ando K., Maeda J., Nagai Y., Yoshizaki T., et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 2005, 1064:136-145.
36. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
37. Zuch C.L., Nordstroem V.K., Briedrick L.A., Hoernig G.R., Granholm A.C., Bickford P.C. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 2000, 427:440-454.
38. Bhattacharjee A.K., Chang L., White L., Bazinet R.P., Rapoport S.I. Imaging apomorphine stimulation of brain arachidonic acid signaling via D2-like receptors in unanesthetized rats. Psychopharmacology 2008, 197:557-566.
39. 2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 2005, 32:405-413.
40. Carson R.E., Wu Y.J., Lang L.X., Ma Y., Der M.G., Herscovitch P., et al. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. J. Cereb. Blood Flow Metab 2003, 23:249-260.
41. 2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with l-DOPA. Synapse (New York, N.Y 2004, 52:218-222.
42. 2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A 2002, 99:11940-11945.
43. Nikolaus S., Larisch R., Beu M., Forutan F., Vosberg H., Muller-Gartner H.W. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 2003, 30:390-395.
44. 2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem Pharmacol 1999, 58:1035-1045.
45. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., et al. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 2001, 86:345-353.
46. Ferre S., Popoli P., Gimenez-Llort L., Rimondini R., Muller C.E., Stromberg I., et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001, 7:235-241.
47. 2A receptors and dopamine D2 receptors. J Biol Chem 2002, 277:18091-18097.